Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰 自愿披露关于BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书的公告 | 2026-03-06 | Chinese | |
| 百奥泰 自愿披露关于Usymro（乌司奴单抗注射液）获得英国MHRA上市批准的公告 | 2026-03-03 | Chinese | |
| 百奥泰 2025年度业绩快报公告 | 2026-02-26 | Chinese | |
| 百奥泰 关于达尔扑拜单抗注射液（BAT4406F）上市许可申请获得受理的公告 | 2026-02-24 | Chinese | |
| 百奥泰 关于Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告 | 2026-02-12 | Chinese | |
| 百奥泰 2026年第一次临时股东会决议公告 | 2026-02-06 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39230911 | 百奥泰 自愿披露关于BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书的公告 | 2026-03-06 | Chinese | ||
| 39230906 | 百奥泰 自愿披露关于Usymro（乌司奴单抗注射液）获得英国MHRA上市批准的公告 | 2026-03-03 | Chinese | ||
| 39230901 | 百奥泰 2025年度业绩快报公告 | 2026-02-26 | Chinese | ||
| 39230897 | 百奥泰 关于达尔扑拜单抗注射液（BAT4406F）上市许可申请获得受理的公告 | 2026-02-24 | Chinese | ||
| 39230894 | 百奥泰 关于Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告 | 2026-02-12 | Chinese | ||
| 39230884 | 百奥泰 2026年第一次临时股东会决议公告 | 2026-02-06 | Chinese | ||
| 39230879 | 百奥泰2026年第一次临时股东会法律意见书 | 2026-02-06 | Chinese | ||
| 39230873 | 百奥泰 自愿披露关于与Avalon Pharma就BAT3306（帕博利珠单抗）注射液签署授权许可及生产、供货和商业化协议的公告 | 2026-02-03 | Chinese | ||
| 39230872 | 百奥泰 关于变更保荐代表人的公告 | 2026-02-02 | Chinese | ||
| 39230867 | 百奥泰2026年第一次临时股东会会议资料 | 2026-01-27 | Chinese | ||
| 39230835 | 百奥泰 2025年年度业绩预亏公告 | 2026-01-27 | Chinese | ||
| 39230826 | 百奥泰 关于归还临时补充流动资金的募集资金的公告 | 2026-01-22 | Chinese | ||
| 39230821 | 百奥泰 关于全资子公司与关联方签订建设工程施工合同暨关联交易的公告 | 2026-01-21 | Chinese | ||
| 39230809 | 百奥泰 关于召开2026年第一次临时股东会的通知 | 2026-01-21 | Chinese | ||
| 39230799 | 百奥泰 自愿披露关于与Gedeon Richter Plc.（吉瑞医药）就BAT2206（乌司奴单抗）注射液签署授权许可及生产、供货和商业化协议收到里程碑付款的进展公告 | 2026-01-13 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.